- Report
- June 2024
- 200 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- January 2022
- 200 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1896EUR$2,000USD£1,584GBP
The Epstein Barr Virus (EBV) is a virus that is part of the herpes family and is one of the most common human viruses. It is the cause of infectious mononucleosis, also known as “mono” or “the kissing disease”. EBV is also associated with certain types of cancer, such as Burkitt’s lymphoma and nasopharyngeal carcinoma.
The EBV drug market is a subset of the infectious diseases drug market. It includes drugs used to treat EBV-related illnesses, such as mono, as well as drugs used to treat EBV-related cancers. These drugs are typically antiviral medications, such as acyclovir, and chemotherapy drugs.
The EBV drug market is highly competitive, with many companies developing and marketing drugs to treat EBV-related illnesses and cancers. Some of the major players in the market include GlaxoSmithKline, Merck, Pfizer, and Bristol-Myers Squibb. Other companies in the market include AstraZeneca, Novartis, and Johnson & Johnson. Show Less Read more